AHA 2007: Physicians are increasingly aware that optimal statin therapy still leaves 50% "residual risk" -- here a well-known authority discusses present and future alternative LDL-C therapies. Medscape Cardiology
AHA 2007: A leading authority discusses whether the ability of the newer generation of beta-blockers to increase NO confers additional benefits for treatment of hypertension and heart failure. Medscape Cardiology
More evidence supporting the idea that rosiglitazone does increase the risk for cardiovascular events has come from a new population-based study of older patients with diabetes. Medscape Medical News
New research shows that a history of hypertension increases the risk for mild cognitive impairment, suggesting that prevention and management of hypertension may lower the risk for cognitive decline. Medscape Medical News
The American Heart Association and the American College of Cardiology have released new recommendations for the treatment of ST-elevation myocardial infarction. Medscape Medical News
The FDA has approved an expanded indication for valsartan tablets, sevelamer carbonate tablets, and new storage conditions for factor VIII/von Willebrand factor complex intravenous injection. Medscape Medical News
Most of the pivotal PAH trials have focused on functional class III/IV patients. Recent studies have included class I/ II patients, suggesting that early treatment of these groups may be beneficial. Medscape Pulmonary Medicine
Two phase 3 trials with the new oral anticoagulant rivaroxaban suggest it is more effective than enoxaparin in preventing venous thromboembolism in patients undergoing major orthopedic surgery. Heartwire
